Publications

Data was pooled from three Phase III, randomized, double-blind, PBO-controlled trials with patients with active r-axSpA who were biologic naïve and previously treated with one or two TNF inhibitors. The study evaluated ASAS40 rates and inflammation measured by serum CRP and spinal or SI joint MRI using individual study data and integrated data.

Although response rates were significant for treatment group, level of inflammation measured by CRP at baseline was not significant in predicting response earlier in the study. It was concluded that Ixekizumab is effective in the treatment of AS/r-axSpA in patients with and without elevated CRP or evidence of spinal inflammation on MRI.